Replies to post #569420 on NorthWest Biotherapeutics Inc (NWBO)

[W_W]

Based on the ASM, Flaskworks process is validated, it can produce vaccine with same results as the manual process vaccine, even at different production rate.

What that means, it means that technically Flaskworks does not have any show stop issues, it is verified and good to go, although before it is certified there are still many formality steps need to go through.

[hoffmann6383]

Flaskworks was acquired well over two years ago as a turnkey system

Utter bullshit. Lots of work was left to do. It wasn't anywhere close to a turnkey system. This bear narrative that flaskworks wasn't ready to go from day 1 is nonsense.

Have a good one Ken!

[biosectinvestor]

That doesn't mean they need the founder of the company in perpetuity as a full time employee after more than 2 years of working with them and there is no indication that what is left to finalize has to do with the equipment. More likely given the stories about sourcing, it is about inputs and other aspects for which his being required to be full time on the payroll is just not necessary. This was likely set out long ago between the company and him and I doubt very highly there is any indication that they cannot ask him questions or consult with him whenever they need. It's not what you suggest. He's not a "key man", there is no "key man" risk - it is a long ago settled acquisition and he put in a lot of time to ensure success and likely wants to get back to his teaching and research. I can't imagine that they do not have a continuing and very good relationship and that he holds considerable shares that very likely he expects to be very valuable in the future.

[Doc logic]

Poor Man -,

NWBO continues learning and improving while demand ramp clearly became a bigger issue than originally planned for. The original iteration of Microden did not produce T-cells but Edens does. Building for the future that NWBO envisions with more options for specific cell characterization is what is absolutely essential for NWBO to stay ahead of the game and to set themselves up to start out and stay at the front of the pack.
Getting the most out of what they have now is what will help the most patients too as not all will be able to do more than give a minimal amount of tumor or monocytes yet still might benefit tremendously as those with significant residual disease still did much better than their SOC counterparts. The other issue that many do not understand is that the trial had more restrictive parameters than the approved product will as compatible donors will at some point be used for monocyte collection and use. All these issues will help increase the number of patients qualifying to be treated so Edens moves much closer to being the answer to help more patients which includes activating a larger population of T-cells in at least some patients.
Edens had plenty to work off of from Microden and I’m sure is much closer to being validated than many think because you don’t get an MIA for “a (commercially available) product” that is not already available or “in process” of approval to be so. If commercially available hinges on Edens then I would think that Edens must be far enough along to warrant the “in process” designation; ). Best wishes.